Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs S&P500 ETF — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B), while S&P500 ETF trades at $778.54 (market cap $821.54B). The key difference: S&P500 ETF is far larger — about 136× Iovance Biotherapeutics Inc. Common Stock's market cap, and S&P500 ETF is more actively traded (40,070,358 versus 14,805,993). Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and S&P500 ETF for 205 Days on average.
| IOVA | SPY | |
|---|---|---|
Market Cap | $6.04B | $821.54B |
Volume | 14,805,993 | 40,070,358 |
Sector | Health | — |
52-Week High | $14.82 | $779.14 |
52-Week Low | $1.81 | $631.99 |
Typical Hold Time | 0 Days | 205 Days |
Enterprise Value | $5.97B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SPY, tracking the S&P 500, trades at $773.97, down 0.42% on the day amid mixed market signals. Technical indicators show a bullish trend with moving averages supporting upside momentum, while oscillators remain neutral. The ETF's fundamentals are tied to the broad U.S. equity market, with no specific company financials available, and a future dividend of $1.89 scheduled for October 2026. Recent news highlights concerns over valuation and profit growth expectations for 2027.
The outlook for SPY is cautiously optimistic, driven by bullish technical trends and seasonal patterns, but risks include potential earnings growth slowdown and elevated market valuations. Investors may find opportunity in broad market exposure, though vigilance on macroeconomic indicators and corporate profit trends is warranted.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
